NCT07213674 - A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

750

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 29, 2028

Study Completion Date

August 30, 2032

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Xaluritamig

Xaluritamig will be administered IV.

DRUG

Abiraterone acetate

Abiraterone acetate will be administered orally.

DRUG

Docetaxel

Docetaxel will be administered IV.

DRUG

Cabazitaxel

Cabazitaxel will be administered IV.

Trial Locations (4)

RECRUITING

Hightower Clinical, Oklahoma City

RECRUITING

City of Hope National Medical Center, Duarte

RECRUITING

City of Hope Orange County Lennar Foundation Cancer Center, Duarte

RECRUITING

Royal Marsden Hospital, Sutton